Nivolumab,Relatlimab
bms
['nivolumab', 'nivo', 'nsclc', 'sclc']
absence of major benefit of adding lag3 inh to nivolumab as neoadjuvant strategy in early stage resectable #nsclc #asco2023 
CEO Gustave Roussy Cancer Campus Paris Saclay University Thoracic oncologist Cofounder Marseille Immunopole Coordinator #ThePioneeRproject Tweets are my own